Skip to main content
. 2020 Aug 18;48(21):11827–11844. doi: 10.1093/nar/gkaa670

Figure 10.

Figure 10.

Exogenously expressed Ago2 loads F12 siRNA (siF12-1, 3 mg/kg) 1–3 weeks after dosing. An AAV vector was designed to express 3xFLAG-tagged mouse Ago2 (FLAG-mAgo2) under a constitutive liver-specific promoter (TBG). (A) Expression of the FLAG-mAgo2 protein was verified in AAV treated mice by Western Blot using an anti-FLAG antibody. Days refer to days post siRNA dose (day 0). FLAG-mAgo2 AAV was injected into three cohorts of mice on day 7 of the experiment (B) Plasma F12 protein levels were quantified by ELISA and normalized to pre-dose for each animal. (C) F12 antisense siRNA liver levels were quantified by RT-qPCR. (D) RISC loading was performed by anti-FLAG IP for both -AAV and +AAV groups (FLAG-mAgo2) and by Ago-APP for -AAV and +AAV groups (Total Ago (APP)). Loaded antisense siRNA was quantified by RT-qPCR. Data is represented as mean ± SD, for N = 3. Welch's independent t-test was utilized to compare the mean value between the control and +AAV groups at each timepoint in (C, D), with statistically significant increases in either liver level or RISC loading shown for the +AAV groups (*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001). Full results for the statistical analysis are included in the Supplemental Information.